Professor of Obstetrics and Gynecology
Obstetrics & Gynecology
Dr. Janet S. Rader, MD
|
|
Give Review
Janet Rader is an expert in the field of Obstetrics & Gynecology. She attended University of Missouri-Columbia School of Medicine. She has 1 awards "CMS Meaningful Use Stage 1 Certification". Dr. Janet S. Rader is a published doctor and has 88 publications published. The lastest was: 'Polymorphisms in immune mediators associate with risk of cervical cancer.' She accepts Medicare payments and is listed with Medicare.gov.
Publications
- Polymorphisms in immune mediators associate with risk of Cervical cancer.
- 3-T MRI-based adaptive brachytherapy for cervix Cancer: Treatment technique and initial clinical outcomes.
- Hypermethylation of miR-203 in endometrial Carcinomas.
- Genetic variations in EGFR and ERBB4 increase susceptibility to Cervical cancer.
- Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent Cervical cancer.
- Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in Cervical cancer.
- The effects of body mass index on complications and survival outcomes in patients with cervical Carcinoma undergoing curative chemoradiation therapy.
- Cost-benefit of laparoscopic versus medical ovarian suppression in premenopausal breast Cancer.
- HLA-Cw group 1 ligands for KIR increase susceptibility to invasive Cervical cancer.
- A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
- Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced...
- Lymph node staging by positron emission tomography in Cervical cancer: relationship to prognosis.
- "Surgical Apgar Score" predicts postoperative complications after cytoreduction for advanced ovarian Cancer.
- Chemoradiation in locally advanced cervical Carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors.
- TP53, MDM2, NQO1, and susceptibility to Cervical cancer.
- Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage Cervical cancer.
- A microRNA expression signature for Cervical cancer prognosis.
- The value of perioperative imaging in patients with Uterine sarcomas.
- Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake.
- CD83 polymorphisms and Cervical cancer risk.
- ATR mutation in endometrioid endometrial Cancer is associated with poor clinical outcomes.
- Long-term assessment of bladder and bowel dysfunction after radical hysterectomy.
- Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6.
- Sequential chemotherapy and irradiation in advanced stage endometrial Cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abd...
- Cardiac arrest during laparotomy with argon beam coagulation of metastatic ovarian Cancer.
- Surveillance FDG-PET detection of asymptomatic recurrences in patients with Cervical cancer.
- Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal Cancer.
- Phase I study and preliminary pharmacology of the novel innate immune modulator rBBX-01 in gynecologic Cancers.
- Identification of novel methylation markers in Cervical cancer using restriction landmark genomic scanning.
- Aberrant expression of oncogenic and tumor-suppressive microRNAs in Cervical cancer is required for cancer cell growth.
- CD83 gene polymorphisms increase susceptibility to human invasive Cervical cancer.
- Evaluation of candidate methylation markers to detect Cervical neoplasia.
- Effect of a T0 radical hysterectomy specimen on survival for early stage Cervical cancer.
- Utility of parametrectomy for early stage Cervical cancer treated with radical hysterectomy.
- Profiling microdissected epithelium and stroma to model genomic signatures for Cervical carcinogenesis accommodating for covariates.
- External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial Cancer.
- Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial Carcinomas of the endometrioid type.
- Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial Cancer.
- Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial Carcinoma.
- Colposcopic accuracy of obstetrics and gynecology residents.
- Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal Cancer.
- Bevacizumab combination therapy in heavily pretreated, recurrent Cervical cancer.
- Identification of chromosomal alterations important in the development of cervical intraepithelial neoplasia and invasive Carcinoma using alignment of DNA microarray d...
- DNA mismatch repair and TP53 defects are early events in Uterine carcinosarcoma tumorigenesis.
- CA-125 response in patients with recurrent ovarian or primary peritoneal Cancer treated with pegylated liposomal doxorubicin or topotecan.
- Cervical tissue collection methods for RNA preservation: comparison of snap-frozen, ethanol-fixed, and RNAlater-fixation.
- MLH3 mutation in endometrial Cancer.
- Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian Carcinoma: A retrospective analysis.
- Long-term outcome of women who undergo panniculectomy at the time of gynecologic surgery.
- Human papillomavirus triage for young women with atypical squamous cells of undetermined significance.
- Preoperative lymph node staging of early-stage cervical Carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography.
- Resource utilization for ovarian Cancer patients at the end of life: how much is too much?
- Cervical sarcomas: an analysis of incidence and outcome.
- Relationship of Ovarian neoplasms and body mass index.
- Human papillomavirus type and tobacco use as predictors of survival in early stage cervical Carcinoma.
- Cervical dysplasia in adolescents.
- FDG-PET evaluation of vaginal Carcinoma.
- Fine mapping and evaluation of candidate genes for Cervical cancer on 11q23.
- Cervix Carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence.
- IGSF4 promoter methylation and expression silencing in human Cervical cancer.
- Cervical Carcinoma in the elderly: an analysis of patterns of care and outcome.
- Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus Cancer.
- Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
- A comparison of stages IB1 and IB2 Cervical cancers treated with radical hysterectomy. Is size the real difference?
- Surgical-pathological predictors of disease-free survival and risk groupings for IB2 Cervical cancer: do the traditional models still apply?
- Panniculectomy: improving lymph node yield in morbidly obese patients with endometrial neoplasms.
- Expression and localization of GRP75 in human epithelial tumors and normal tissues.
- Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history.
- Double cervix with bilateral and synchronous HSIL associated with different high-risk HPV types. A case report.
- Synchronous ovarian metastases at the time of laparotomy for colon Cancer.
- Increased risk for hereditary nonpolyposis colorectal Cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive ...
- Denaturing high-performance liquid chromatography for detecting and typing genital human papillomavirus.
- Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies.
- Acute abdominal pain with a calcified Pelvic mass.
- Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies.
- Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenoCarcinoma.
- Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial Cancers.
- Primary peritoneal Carcinoma presenting as adenoCarcinoma on a Pap smear. A case report.
- The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies.
- Ribosomal DNA methylation in patients with endometrial Carcinoma: an independent prognostic marker.
- Utility and cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients.
- Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar Cancer.
- Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous Carcinoma of the cervix: a gynecologic oncology group study.
- Use of complementary and alternative medicine among women with gynecologic Cancers.
- Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial Carcinoma: a Gynecologic Oncology Group Study.
- Epithelial Ovarian tumors of low malignant potential: the role of microinvasion.
- AKT Inhibitors Promote Cell Death in Cervical Cancer through Disruption of mTOR Signaling and Glucose Uptake.
Schools
University Of MissouriColumbia School Of Medicine
Michael Reese
Johns Hopkins
Procedures Preformed
- Cancer Treatment
- Colporrhaphy
- Colposcopy
- Contraceptive Management
- View All
Conditions Treated
- Carcinoma in Situ
- Cervical Cancer
- Chronic Pelvic Pain
- Endometriosis
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Johns Hopkins University -
University of Missouri-Columbia School of Medicine
Hospital
-
Children's Hospital of Wisconsin -
Froedtert Memorial Lutheran Hospital
Drug Facts
| NPI NUMBER | 1316965098 | |
| NPPES Provider LastName | RADER | |
| NPPES Provider FirstName | JANET | |
| NPPES Provider ZIPCode | 532263522 | |
| NPPES Provider State | WI | |
| Specialty Description | Gynecological/Oncology | |
| Total Claim Count | 112.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1316965098 |
| Last Name Of The Provider | RADER |
| First Name Of The Provider | JANET |
| View All |
Similar Doctors
|
Dr. Raj Narayan, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Paul D. Ginkel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Scott A. Kamelle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William Bradley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul D. Burstein, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ali Mahdavi, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Denise Uyar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne Martinelli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca A. Mokrohisky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James G. Linn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary Burke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Annamarie B. Windsor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicole P. Salvo, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Kathy King, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie A. Webb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward E. Resnik, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jessica L. Gremp, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erika S. Lubsey, MD
This Doctor is OpenDoctor Recommended.
|